(VIANEWS) – Century Communities (CCS), Mercury General Corporation (MCY), Halozyme Therapeutics (HALO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Century Communities (CCS)
31.1% sales growth and 12.64% return on equity
Century Communities, Inc., together with its subsidiaries, engages in the design, development, construction, marketing, and sale of single-family attached and detached homes. It is also involved in the entitlement and development of the underlying land; and provision of mortgage, title, and insurance services to its home buyers. The company offers homes under the Century Communities and Century Complete brands. It sells homes through its sales representatives, as well as through independent real estate brokers in 17 states in the United States. Century Communities, Inc. was founded in 2002 and is headquartered in Greenwood Village, Colorado.
Earnings Per Share
As for profitability, Century Communities has a trailing twelve months EPS of $9.01.
PE Ratio
Century Communities has a trailing twelve months price to earnings ratio of 8.79. Meaning, the purchaser of the share is investing $8.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.64%.
2. Mercury General Corporation (MCY)
29.3% sales growth and 14.04% return on equity
Mercury General Corporation, together with its subsidiaries, engages in writing personal automobile insurance in the United States. It also writes homeowners, commercial automobile, commercial property, mechanical protection, fire, and umbrella insurance. The company's automobile insurance products cover collision, property damage, bodily injury, comprehensive, personal injury protection, underinsured and uninsured motorist, and other hazards; and homeowners' insurance products cover dwelling, liability, personal property, fire, and other hazards. It sells its policies through a network of independent agents, 100% owned insurance agents, and direct channels in Arizona, California, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas, and Virginia. The company was founded in 1961 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Mercury General Corporation has a trailing twelve months EPS of $3.89.
PE Ratio
Mercury General Corporation has a trailing twelve months price to earnings ratio of 13.57. Meaning, the purchaser of the share is investing $13.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.04%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.1%, now sitting on 4.8B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 270.2% and a drop 56.1% for the next.
Volume
Today’s last reported volume for Mercury General Corporation is 59909 which is 74.19% below its average volume of 232198.
3. Halozyme Therapeutics (HALO)
26.5% sales growth and 261.68% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.41.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 22.34. Meaning, the purchaser of the share is investing $22.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 261.68%.
Moving Average
Halozyme Therapeutics’s value is way above its 50-day moving average of $46.28 and way above its 200-day moving average of $39.97.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $53.83 at 11:22 EST, below its 52-week high of $54.35 and way higher than its 52-week low of $32.83.
Volume
Today’s last reported volume for Halozyme Therapeutics is 1095070 which is 7.49% below its average volume of 1183780.
Sales Growth
Halozyme Therapeutics’s sales growth is 4.5% for the current quarter and 26.5% for the next.
4. Vertex (VERX)
13.9% sales growth and 3.26% return on equity
The zacks analyst blog asml, sap, NVIDIA, vertex and essilorluxxotticaWhile CF remains the main area of focus, Vertex is also developing treatments for, Stocks recently featured in the blog include: ASML (ASML Quick QuoteASML – Free Report) , SAP (SAP Quick QuoteSAP – Free Report) , Nvidia (NVDA Quick QuoteNVDA – Free Report) , Vertex Pharma (VRTX Quick QuoteVRTX – Free Report) and EssilorLuxxottica (ESLOY Quick QuoteESLOY – Free Report) .
Vertex, Inc. provides tax technology solutions for corporations in retail, leasing, communication, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also offers implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Vertex has a trailing twelve months EPS of $0.05.
PE Ratio
Vertex has a trailing twelve months price to earnings ratio of 721. Meaning, the purchaser of the share is investing $721 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.26%.
Volume
Today’s last reported volume for Vertex is 8767740 which is 740.67% above its average volume of 1042940.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 596.42M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 62.5% and 20%, respectively.
Previous days news about Vertex(VERX)
- Vertex pharmaceuticals (vrtx) exceeds market returns: some facts to consider. According to Zacks on Monday, 15 July, "Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertex Pharmaceuticals. ", "In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 28.72. "
